Z
Zhenquan Hu
Researcher at Chinese Academy of Sciences
Publications - 20
Citations - 671
Zhenquan Hu is an academic researcher from Chinese Academy of Sciences. The author has contributed to research in topics: ABL & Tyrosine kinase. The author has an hindex of 11, co-authored 20 publications receiving 389 citations. Previous affiliations of Zhenquan Hu include University of Basel.
Papers
More filters
Journal ArticleDOI
Using PyMOL as a platform for computational drug design
TL;DR: An extensive discussion on various molecular modeling modules in PyMOL, covering those for visualization and analysis enhancement, protein–ligand modeling, molecular simulations, and drug screening are presented.
Journal ArticleDOI
OpenVirtualToxLab—A platform for generating and exchanging in silico toxicity data
TL;DR: The VirtualToxLab is an in silico technology for estimating the toxic potential--endocrine and metabolic disruption, some aspects of carcinogenicity and cardiotoxicity--of drugs, chemicals and natural products by interactively analyzing the binding mode of a compound with its target protein(s) in real-time 3D.
Journal ArticleDOI
W2466.48 Opens a Gate for a Continuous Intrinsic Water Pathway during Activation of the Adenosine A2A Receptor
TL;DR: Molecular dynamics simulations are used to reveal distinct conformational transitions of the adenosine A2A receptor, and it is found that the conserved W246(6.48) residue in transmembrane helix TM6 performs a key rotamer toggle switch.
Journal ArticleDOI
Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC
Yongfei Chen,Jiaxin Wu,Aoli Wang,Ziping Qi,Taoshan Jiang,Cheng Chen,Fengming Zou,Chen Hu,Wei Wang,Hong Wu,Zhenquan Hu,Wenchao Wang,Beilei Wang,Li Wang,Tao Ren,Shanchun Zhang,Qingsong Liu,Jing Liu +17 more
TL;DR: A highly potent EGFR/ALK dual kinase inhibitor compound 18 (CHMFL-ALK/EGFR-050), which potently inhibited EGFR L858R, del 19 and T790M mutants as well as EML4-ALK, R1275Q, L1196M, F1174L and C1156Y mutants biochemically and significantly suppressed the tumor growth in H1975 cell inoculated xenograft model.
Journal ArticleDOI
Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML
Aoli Wang,Xixiang Li,Cheng Chen,Cheng Chen,Hong Wu,Ziping Qi,Chen Hu,Chen Hu,Kailin Yu,Kailin Yu,Jiaxin Wu,Jiaxin Wu,Juan Liu,Xiaochuan Liu,Zhenquan Hu,Wei Wang,Wenliang Wang,Wenliang Wang,Wenchao Wang,Li Wang,Li Wang,Beilei Wang,Beilei Wang,Qingwang Liu,Lili Li,Jian Ge,Tao Ren,Shanchun Zhang,Ruixiang Xia,Jing Liu,Qingsong Liu +30 more
TL;DR: A new type II FLT3 kinase inhibitor, compound 14 (CHMFL-FLT3-213), is discovered, which exhibited highly potent inhibitory effects against FLT 3-ITD mutant and associated oncogenic mutations.